Clinical trials: Dementia Alzheimers
Alzheimer Disease, Aerobic Exercise
The Effects of Exercise Program in Alzheimer's Patients With Mild to Moderate Stage Alzheimer's Disease
The primary aim of this trial is to investigate the feasibility of an exercise program consisting of respiratory exercises, aerobic exercises and strengthening exercises in mild to moderate Alzheimer's disease.
- Conditions
- Alzheimer Disease, Aerobic Exercise, Breathing Exercise, Resistance Training
- Trial name
- NCT04021888
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Dokuz Eylul University
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease
Virtual Reality Cognitive Therapy for Alzheimer's Disease
To evaluate the usability, feasibility, and acceptability of VRCT iteratively on 36 AD/ADRD individuals with mild to moderate CI.
- Trial name
- VRCT (NCT05788848)
- Testing
- VRCT
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Claritytek, Inc.
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Cognitive Impairment, Dementia
Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
The aim of this multicenter, cross-sectional, observational flash mob study is to investigate the prevalence of cognitive impairment in hospitalized elderly aged 65 years or older, and the recognition of cognitive impairment by…
- Conditions
- Cognitive Impairment, Dementia, Alzheimer Disease, Delirium
- Trial name
- NCT05395559
- Where
- Netherlands
- Volunteers
- 757 people
- Sponsor
- University Medical Center Groningen
Alzheimer Disease, Depression
Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression
The global aim of our study is to validate eye movement recording as an early differential diagnostic tool, in order to discriminate as early as possible between neurodegenerative dementias of Alzheimer type and depressive…
- Trial name
- MOMAD (NCT01434940)
- Testing
- Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam
- Where
- France
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment
Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to…
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Trial name
- DIALCAT (NCT03578991)
- Testing
- Smart pillbox, Interactive digital platform
- Where
- 8 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Parc Sanitari Pere Virgili
Dementia Alzheimers
Assessing an Intergenerational Music Program Delivered by Adolescents to Older Adults With Declining Cognition
Intergenerational music programming has been shown to benefit both young people and older adults in terms of quality of life, social connection, and promotion of positive cross-age attitudes.
- Trial name
- NCT04645017
- Testing
- Intergenerational Music Program
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pittsburgh
Alzheimer's Disease
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
- Trial name
- NCT01467726
- Testing
- Velusetrag
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alfasigma S.p.A.
Alzheimer's Disease
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease
The primary purpose of this study is to evaluate the safety and the efficacy of (Human Umbilical Cord-Derived Mesenchymal Stem Cells) UCMSCs for patients with Alzheimer's disease (AD).
- Trial name
- SEESUPAD (NCT02672306)
- Testing
- UCMSCs
- Where
- China
- Volunteers
- 16 people
- Sponsor
- South China Research Center for Stem Cell and Regenerative Medicine
Anxiety Disorders, Dementia
Cognitive Behavior Therapy for Treating Anxiety in People With Dementia
This study will evaluate the effectiveness of cognitive behavioral therapy in treating anxiety in older adults with dementia.
- Trial name
- NCT00596284
- Testing
- Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD), Enhanced Usual Care (EUC)
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Baylor College of Medicine
Alzheimer's Disease
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
An open-label, proof-of-concept study to evaluate the safety and treatment effects of SLS-005 in Participants with Alzheimer's Disease (AD) treated once or twice weekly for 52 weeks.
- Trial name
- [STRIVE-AD] (NCT05332678)
- Testing
- SLS-005 - Once Weekly, SLS-005 - Twice Weekly
- Where
- 3 sites in Australia
- Sponsor
- Seelos Therapeutics, Inc.
Alzheimer Disease
REGEnLIFE RGn530 - Feasibility Pilot
REGEnLIFE RGn530 is a photobiomodulation medical device, consisting in a modular helmet and abdominal panel, composed of near-infrared low-level lasers (LLLT), near-infrared and red LEDs as well as a static magnetic field.
- Trial name
- NCT03672474
- Testing
- Photobiomodulation REGEnLIFE RGn530 device
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Mild Cognitive Impairment (MCI), Dementia
An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)
This study tests an innovative system and service for collecting objective, consistent, and in-community gait parameters suitable for use as AD/ADRD biomarkers.
- Trial name
- NCT07127133
- Testing
- Insole and ankle device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Mild Cognitive Impairment, Dementia
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance…
- Conditions
- Mild Cognitive Impairment, Dementia, Subjective Cognitive Decline (SCD), Alzheimer Disease
- Trial name
- JOY-ALZ (NCT06889818)
- Where
- 3 sites in South Korea
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ewha Womans University Mokdong Hospital
Alzheimer's Disease
Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease
The purpose of this study is to accept or reject the hypothesis that Lu AE58054 improves cognition and functional outcomes in patients with moderate Alzheimer's Disease, already in treatment with donepezil.
- Trial name
- NCT01019421
- Testing
- Lu AE58054
- Where
- 51 sites in Australia, Canada and 5 more
- Volunteers
- 278 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease, Subjective Cognitive Decline
German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)
The SCD-Q (Subjective Cognitive Decline-Questionnaire) is an established instrument to quantify self-perceived cognitive decline. Both self- and informant-rated versions of the SCD-Q are available.
- Trial name
- NCT06711952
- Testing
- Subjective Cognitive Decline-Questionnaire (SCD-Q), Cognitive Failure Questionnaire (CFQ), biomarkers
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Alzheimer's Disease
Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression
It is currently accepted that depression during midlife is a risk factor for Alzheimer's disease (AD). Furthermore, several prospective population studies have demonstrated that depression is an independent risk factor for…
- Trial name
- LIDEAL (NCT02303158)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Alzheimer Disease, Sleep Initiation and Maintenance Disorders
Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease
This study will compare four different behavioral treatment programs to determine which is most effective in reducing night-time disturbances in individuals with Alzheimer's disease (AD).
- Trial name
- NCT00183378
- Testing
- Walking Program, Light Exposure Program, Combined Education, Walking and Light Exposure Program
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- University of Washington
Alzheimer Disease
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
To access the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00498602
- Testing
- ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline
- Where
- 27 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.